

ATTACHMENT A

SCHEDULE OF DOCUMENTS - FOI 2555

Doc no.	Date	Pages	Description	Decision on access¹	Exemption
1	15 August 2020	1	SITAG Meeting Agenda	R	
2	21 August 2020	2	SITAG Meeting Outcomes	RIE	Section 22 (part) Section 45 (part) Section 47C (part)
3	21 August 2020	1	SITAG Meeting Agenda	R	
4	8 September 2020	2	SITAG Meeting Outcomes	RIE	Section 22 (part) Section 45 (part) Section 47C (part)
5	8 September 2020	1	SITAG Meeting Agenda	R	
6	16 September 2020	3	SITAG Meeting Outcomes	RIE	Section 22 (part) Section 33 (part) Section 47C (part) Section 47F (part)
7	16 September 2020	1	SITAG Meeting Agenda	R	
8	16 September 2020	2	SITAG Meeting Outcomes	RIE	Section 22 (part) Section 33 (part) Section 45 (part) Section 47C (part)

¹ R = Release, RIE = Release with Irrelevant and Exempt information removed.



Australian Government
Department of Health

AGENDA

**COVID-19 Vaccine and Treatments for Australia
Science and Industry Technical Advisory Group**

Sunday, 16 August 2020, 2pm-3pm

Dial in details:

To join the meeting, please dial:

(02) 8016 6192

Participant PIN: 112 159#

Chair:

Dr Brendan Murphy, Secretary, Department of Health

Agenda Item	Lead
1. Welcome and introductions	Brendan Murphy
2. Declaration of conflicts of interest	All
3. Role and responsibility <ul style="list-style-type: none">a. Terms of Referenceb. Confidentiality requirements	Brendan Murphy
4. COVID-19 Landscape <ul style="list-style-type: none">a. Global overviewb. Australia's COVID-19 Vaccine and Treatment Strategyc. Australian Government COVID-19 Vaccine State of Play for week ending 14 August 2020	Brendan Murphy
5. Candidate discussion <ul style="list-style-type: none">a. University of Oxford / AstraZeneca	All
6. Close and next meeting	Brendan Murphy

Meeting Outcomes

COVID-19 Vaccine and Treatments for Australia - Science and Industry Technical Advisory Group

Meeting 1: Sunday, 16 August 2020, 2pm-3pm

Attendance:

- *Ex-officio members:* Prof Paul Kelly; A/Prof Chris Blyth; Prof Allen Cheng; Dr Alan Finkel AO; Dr Larry Marshall; Prof Andrew Wilson
- *Independent nominees:* Mr John Anderson; Mr Rob Hetherington; Ms Sue MacLeman; Ms Kirsten O’Doherty; Dr Felicia Pradera; Mr Mark Sullivan
- *Australian-Government observers:* Caroline Edwards, John Skerritt, s 22 Lisa Schofield, s 22 Note taker: s 22

Agenda Item (Lead) and included papers	Meeting Outcomes
<p>1. Welcome and introductions (Brendan Murphy)</p> <p><i>Papers: Agenda</i></p>	<ul style="list-style-type: none"> • Meeting commenced at 2.10pm. • The Chair outlined the conflict of interest and confidentiality processes. • Independent members introduced themselves.
<p>2. Declaration of conflicts of interest (All)</p> <p><i>Papers: Nil</i></p>	<ul style="list-style-type: none"> • Participants declared conflicts of interest. • The Chair agreed that these conflicts of interest could be managed. • The Department of Health will record all conflicts in a register.
<p>3. Role and responsibility a. Terms of Reference b. Confidentiality requirements (Brendan Murphy)</p> <p><i>Papers: 3a TOR; 3b Confidentiality Deed</i></p>	<ul style="list-style-type: none"> • The Chair referred to the Terms of Reference and noted that this group will advise particularly on the procurement and manufacturing decisions and intellectual property considerations, as part of a diversified investment approach. s 47C
<p>2. COVID-19 Landscape a. Global overview b. Australia’s COVID-19 Vaccine and Treatment Strategy c. Australian Government COVID-19 Vaccine State of Play for week ending 14 August 2020 (Brendan Murphy)</p> <p>s 45 4b Vaccine Strategy; 4c State of Play</p>	<ul style="list-style-type: none"> • The Chair provided an update on the Australian Government’s position with respect to COVAX.

<p>3. Candidate discussion a. University of Oxford / AstraZeneca (All)</p> <p><i>Papers: 5a Oxford-AZ overview; 5a Proposed letter of intent; Unnumbered – articles by Graham et. al and Folegatti et. al</i></p>	<ul style="list-style-type: none">• The Chair asked for nominees to indicate their view of progressing an agreement with AstraZeneca, starting with a letter of intent.• All were supportive: s 47C • Responses to questions were provided by the Chair and Lisa Schofield. s 47C
<p>4. Close and next meeting (Brendan Murphy)</p>	<ul style="list-style-type: none">• The Chair opened the floor to other questions.<ul style="list-style-type: none">○ A nominee raised a potential global paracetamol shortage; John Skerritt noted stocks were reasonable at this stage.• Meeting closed at 3.19pm.

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH



Australian Government
Department of Health

AGENDA

**COVID-19 Vaccine and Treatments for Australia
Science and Industry Technical Advisory Group**

Monday 24 August 2020, 2.30pm – 4.00pm

Dial in details:

To join the meeting, please dial:

Phone: 02 8016 6192

Participant passcode: 28 63 27

Chair:

Dr Brendan Murphy, Secretary, Department of Health

Agenda Item	Lead	Papers
1. Welcome and introductions <ul style="list-style-type: none"> a. Disclosure and management of interests b. Endorse outcomes of previous meeting 	Brendan Murphy	1. a. i) Register of interests 1. b. i) Meeting outcomes – 16 August ii) Letter from Chair to Minister Hunt on meeting outcomes – 17 August
2. Update on recent developments <ul style="list-style-type: none"> a. Prime Minister's announcements b. State of play 	Brendan Murphy	2. a. i) Media release – New deal secures potential COVID-19 vaccine for every Australian – 19 August ii) Signed Letter of Intent – AstraZeneca iii) Australia's COVID-19 Vaccine and Treatment Strategy – Publication 2. b. i) Australian Government Vaccines and Treatments – State of Play – 21 August ii) Global Vaccines and Treatments Landscape – 21 August
3. Media and company engagement	Brendan Murphy	3. Media and company engagement
4. Candidate discussion <ul style="list-style-type: none"> a. University of Oxford/AstraZeneca b. University of Queensland/CSL 	All	4. a. i) AstraZeneca draft agreement overview 4. b. i) UQ/CSL Vaccine Candidate Overview ii) COVID-19 Sclamp Candidate Vaccine Update (UQ) iii) Seqirus draft agreement overview
5. Close and next meeting	Brendan Murphy	




Meeting Outcomes

COVID-19 Vaccine and Treatments for Australia - Science and Industry Technical Advisory Group
 Meeting 2: Monday 24 August 2020, 2.30pm-4.00pm

Attendance:

- *Ex-officio nominees:* Prof Paul Kelly; A/Prof Chris Blyth; Prof Allen Cheng; Dr Alan Finkel AO; Dr Larry Marshall; Prof Andrew Wilson
- *Independent nominees:* Mr John Anderson; Mr Rob Hetherington; Ms Sue MacLeman; Ms Kirsten O’Doherty; Dr Felicia Pradera; Mr Mark Sullivan
- *Australian-Government observers:* Caroline Edwards, John Skerritt, s 22 Lisa Schofield, s 22 Note takers: s 22 s 22

Agenda Item (Lead) and included papers	Meeting Outcomes
<p>1. Welcome and introductions</p> <ul style="list-style-type: none"> a. Disclosure and management of interests (1.a.i) b. Endorse outcomes of previous meeting (paper 1.b.i, 1.b.ii) 	<ul style="list-style-type: none"> • Meeting opened at 2:00pm. • s 47C • Participants declared conflicts of interest. • The Chair agreed that these conflicts of interest could be managed. • The Department of Health will record all conflicts in a register. • Members endorsed the outcomes of the previous meeting (16 August) and supported the position sought by the Australian Government. Members agreed engagement with COVAX was prudent.
<p>2. Update on recent developments</p> <ul style="list-style-type: none"> a. Prime Minister’s announcements (papers 2.a.i-iii) b. State of play – candidates (papers 2.b.i and 2.b.ii) 	<ul style="list-style-type: none"> • The Chair provided a brief update on announcements made since the last meeting: the letter of intent with AstraZeneca, s 45 and the publication of the COVID-19 Vaccines and Treatments Strategy. • Members noted summaries of vaccine candidates.
<p>3. Media and companies Handling approaches from the media and companies (paper 3)</p>	<ul style="list-style-type: none"> • Members noted media interest in recent day. Members agreed to direct any enquiries and approaches from companies to the department has per the handling note.

<p>4. Discussion of vaccine candidates</p> <p>a. University of Oxford/AstraZeneca (paper 4.a.i)</p> <p>b. University of Queensland/CSL (papers 4.b.i-iv)</p>	<ul style="list-style-type: none"> Members noted progress on a definitive agreement with AstraZeneca and endorsed the finalisation of the agreement. ^{s 47C} Questions and comments were raised s 47C <p>The Chair, Lisa Schofield and John Skerritt responded to questions.</p> <ul style="list-style-type: none"> The Chair introduced the UQ vaccine candidate. s 47C The Chair responded to questions from members. The Chair sought confirmation of views from each member on the proposal to enter into an agreement with Seqirus with respect to the UQ candidate. s 45 <p style="text-align: center;">  </p> <p style="text-align: center;">  </p> <p style="text-align: center;">  </p> <ul style="list-style-type: none"> In general the group supported entering into an agreement for the advance purchase of the UQ vaccine s 47C
<p>5. Close and next meeting</p>	<ul style="list-style-type: none"> The Chair opened the floor to other questions. s 47C Meeting closed at 4.15pm.



Australian Government
Department of Health

AGENDA

**COVID-19 Vaccine and Treatments for Australia
Science and Industry Technical Advisory Group**

Wednesday 9 September 2020, 1.30pm – 3.00pm

Meeting details updated in calendar invite

Chair: Dr Brendan Murphy, Secretary, Department of Health

Agenda Item	Lead	Papers
1. Welcome and introductions a. Updated deed of confidentiality b. Disclosure and management of interests c. Endorse outcomes of previous meeting	Brendan Murphy	1. b. i) Register of interests 1. c. i) Meeting outcomes – 24 August ii) Letter from Chair to Minister Hunt on meeting outcomes – 24 August
2. Update on recent developments (for noting) a. Prime Minister's announcements b. State of play	Brendan Murphy	2. a. i) Media release – Australia secures onshore manufacturing agreements for two COVID-19 vaccines – 7 September 2. b. i) Australian Government Vaccines and Treatments – State of Play – 4 September ii) Global Vaccines and Treatments Landscape – 27 August
3. Future investments a. Building a diverse global portfolio b. Nucleic acid vaccines	Lisa Schofield Larry Marshall	3. a. i) Principles, including current state of negotiations ii) Possible portfolio 3. b. i) Nucleic acid vaccines overview and presentation
4. Manufacturing capacity and capability stocktake a. Vaccines preparedness	David Luchetti	4. a. i) Draft interim report: capacity and capability stocktake - vaccines preparedness
5. Therapeutic developments	Brendan Murphy	5. a. i) Therapeutics stocktake and strategic approach ii) COVID-19 treatment trials iii) Government funding iv) WHO guidance
6. Close and next meeting	Brendan Murphy	

Meeting Outcomes

COVID-19 Vaccine and Treatments for Australia - Science and Industry Technical Advisory Group
Meeting 3: Wednesday 9 September 2020, 1:30pm-3pm

Attendance:

- *Chair:* Dr Brendan Murphy
- *Ex-officio members:* A/Prof Chris Blyth; Prof Allen Cheng; Dr Alan Finkel AO; Dr Larry Marshall; Prof Andrew Wilson; Prof. Michael Kidd obo Prof. Paul Kelly.
- *Independent members:* Mr John Anderson; Mr Rob Hetherington; Ms Sue MacLeman; Ms Kirsten O’Doherty; Dr Felicia Pradera; Mr Mark Sullivan
- *Australian-Government observers:* Dr Jane Cook, s 22 Ms Lisa Schofield, s 22
Note taker: s 22
- *Invited guest speakers:* Prof Trevor Drew, Dr Keith McLean (Item 3.b.i, Item 4).
- *Probity Advisor:* Mr Mark Harrison

Agenda Item (Lead) and included papers	Meeting Outcomes
<p>1. Welcome and introductions</p> <ul style="list-style-type: none"> a. Updated deed of confidentiality b. Disclosure and management of interests (paper 1.b.i) c. Endorse outcomes of previous meeting (papers 1.c.i, 1.c.ii) 	<ul style="list-style-type: none"> • Meeting opened at 1:35pm. • The Chair thanked members for the completion of their appointment paperwork and noted that the appointments process had been finalised. • The Chair noted conflicts of interest regarding Item 4: s 47F The Chair agreed that these conflicts could be managed. • The Department of Health will record all conflicts in the register. • Members endorsed the outcomes of the previous meeting (24 August) and noted the letter from Dr Murphy to Minister Hunt on the outcomes from the last meeting.
<p>2. Update on recent developments</p> <ul style="list-style-type: none"> a. Prime Minister’s announcements (papers 2.a.i-iii) b. State of play – candidates (papers 2.b.i and 2.b.ii) 	<ul style="list-style-type: none"> • The Chair provided a brief update on announcements made since the last meeting: Oxford/AZ and UQ/CSL to provide more than 84.8 million vaccine doses throughout 2021, with 3.8 million doses of the Oxford vaccine to be available in Jan and Feb 2021 (media release at 2.a.i) • Members noted the recent media regarding a single adverse event in the Oxford University clinical trial, acknowledging the nature and cause of the event had not been confirmed by AZ.
<p>3. Future Investments</p> <ul style="list-style-type: none"> a. Building a diverse global portfolio (3.a. i, 3.a. ii) b. Nucleic acid vaccine overview and presentation (papers 3.b.i) 	<ul style="list-style-type: none"> • Members noted the summary table on the current stage of vaccine negotiations and engagements, including the continuing role of the COVAX Facility in the strategy. • Ms Schofield provided brief overview of current state of negotiations and portfolio, and led discussion on principles for building a diverse portfolio.

	<ul style="list-style-type: none">• Members were asked to consider options to structure the portfolio, including access, volume availability, manufacturing capability and vaccine platforms.• Questions and comments were raised s 47C • Dr Murphy and Ms Schofield addressed these questions.• s 47C and future investments will likely need to be manufactured offshore. Members noted the risk of relying on a single manufacturer.• Members discussed new and emerging technology platforms, and noted a portfolio could comprise both experienced and more novel technologies.• s 47C• Members agreed that diversification of the portfolio is a priority, and that technology platforms should be part of this consideration.• s 47F joined the meeting – 1:55pm.• s 47F provided members an overview of mRNA vaccines, noting storage considerations, stability of candidates, manufacturing options and cohorts.• Members noted that Moderna and Pfizer are continuing to focus research on stability and storage conditions for the vaccines that would improve opportunities for distribution and deployment.• s 47C• s 47C• s 47C
--	--

THIS DOCUMENT HAS BEEN RELEASED UNDER THE FREEDOM OF INFORMATION ACT BY THE ARCHIVES OF SEQUOIA COUNTY

<p>4. Manufacturing capacity and capability stocktake a. Vaccines preparedness (4.a. i)</p>	<ul style="list-style-type: none"> • The Chair introduced s 22 to lead this item. • s 33 • Members observed that the submissions received represent a cross-section of onshore capacity and capability. • Members noted that the current focus is on supporting the next 6-12 months, and therefore existing capability was targeted as part of the survey. • Members considered the possibility of brokering agreements between separate manufacturers to develop end-to-end manufacturing capacity.
<p>5. Therapeutic developments (5.a.i, 5.a.ii, 5.a.iii, 5.a.iv).</p>	<ul style="list-style-type: none"> • The Chair carried forward this item to the next meeting due to time constraints. • Ms Schofield welcomed early feedback from members on therapeutics and treatments via email prior to the next meeting.
<p>6. Close and next meeting</p>	<ul style="list-style-type: none"> • The Chair closed the meeting at 3:05pm and advised that the next meeting would occur in the week commencing 14 September.

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH



Australian Government

Department of Health

AGENDA

COVID-19 Vaccine and Treatments for Australia Science and Industry Technical Advisory Group

Thursday 17 September 2020, 12.30pm – 1:30pm

Meeting details updated in calendar invite

Chair: Dr Brendan Murphy, Secretary, Department of Health

Agenda Item	Lead	Papers
1. Welcome and introductions a. Disclosure and management of interests b. Endorse outcomes of previous meeting	Brendan Murphy	1. a. i) Register of interests 1. b. i) Meeting outcomes – 9 September
2. Update on recent developments (for noting) a. State of play	Brendan Murphy	2. a. i) Australian Government Vaccines and Treatments – State of Play – 11 September ii) Global Vaccines and Treatments Landscape – 11 September
3. Future investments a. Building a diverse global portfolio	Lisa Schofield	3. a. i) Framework for advance investment for COVID-19 vaccines ii) Proposed next investments
4. Therapeutic developments	Brendan Murphy	4. a. i) Therapeutics stocktake and strategic approach ii) COVID-19 treatment trials iii) Government funding iv) WHO guidance
5. Close and next meeting	Brendan Murphy	

Meeting Outcomes

COVID-19 Vaccine and Treatments for Australia - Science and Industry Technical Advisory Group

Meeting 4: Thursday 17 September 2020, 12:30pm- 1:30pm

Attendance:

- *Chair:* Dr Brendan Murphy
- *Ex-officio members:* A/Prof Chris Blyth; Prof Allen Cheng; Dr Alan Finkel AO; Dr Larry Marshall; Prof Andrew Wilson; Prof. Paul Kelly.
- *Independent members:* Mr John Anderson; Mr Rob Hetherington; Ms Sue MacLeman; Ms Kirsten O’Doherty; Dr Felicia Pradera; Mr Mark Sullivan
- *Australian-Government observers:* Adj Prof John Skerritt, s 22 Ms Lisa Schofield, s 22 Note taker: s 22
- *Probity Advisor:* s 47F

Agenda Item (Lead) and included papers	Meeting Outcomes
1. Welcome and introductions <ul style="list-style-type: none"> a. Disclosure and management of interests b. Endorse outcomes of previous meeting 	<ul style="list-style-type: none"> • Meeting opened at 12:32pm. • The Chair reminded members of conflict of interest obligations and asked members if there were any new conflicts to be raised. • There were no new conflicts of interests raised at this time. • Members endorsed the outcomes of the previous meeting (9 September).
2. Update on recent developments <ul style="list-style-type: none"> a. State of play (papers 2.a.i, 2.a.ii) 	<ul style="list-style-type: none"> • Members noted the updates provided by the Department and s 45 noting some new information was now available including the recommencement of the Astra Zeneca clinical trial in some countries.
3. Future Investments <ul style="list-style-type: none"> a. Building a diverse global portfolio (3.a.i, 3.a. ii) 	<ul style="list-style-type: none"> • Ms Schofield provided members with an overview of a prioritisation framework that could be applied to support decision making for future investments. • Members discussed the framework, and noted that it covered key elements for building a portfolio, noting the technology platform criteria could be expanded to provide weighting for diversity in the portfolio or where other jurisdictions have made investments. • s 33 • Members discussed the distribution and logistical challenges of mRNA vaccines, where storage conditions, at potentially -70 degrees could limit vaccination providers. Vaccine administration and consumables, including normal saline, were discussed as key parts of implementing this vaccine platform. • Ms Schofield noted that in the previous meeting, s 47C had been identified as the most progressed at this time with draft terms provided to the department– those from s 47C

	<p>s 47C – and had been mapped to the proposed prioritisation framework. Members noted the scoring that had been applied to the s 47C vaccine candidates and agreed that scoring was aligned to the information available from the companies.</p> <ul style="list-style-type: none"> Members agreed to continuing discussions with all s 47C in relation to their vaccine candidates. Members agreed advance purchase agreement discussions to continue with Pfizer and Novavax as a priority, s 47C
<p>4. Therapeutic developments (for discussion) (4.a.i, 4.a.ii, 4.a.iii, 4.a.iv).</p>	<ul style="list-style-type: none"> The Chair introduced the therapeutic developments item, and asked members to consider what other therapeutic modalities or molecules the Government should be pursuing at this time. Members discussed the large number of clinical trials occurring globally, and noted the different phases of the disease that impact on treatment options. The Chair noted that the value of steroids has been demonstrated, s 45 Members noted that to date, there has been a significant focus on the procurement of vaccines. s 47C s 33 Members agreed that more information and improved data is required to support decisions in regard to treatments for COVID-19.
<p>5. Close and next meeting</p>	<ul style="list-style-type: none"> s 33 s 22 Ms Schofield advised members that a placeholder for the next meeting will be sent out for 24 September, if required, and meeting papers may be provided out-of-session. The Chair closed the meeting at 1:33pm.

THIS DOCUMENT HAS BEEN RELEASED UNDER THE FREEDOM OF INFORMATION ACT 1992 BY THE DEPARTMENT OF HEALTH